{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:32:40Z","timestamp":1760189560943},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Rheumatology division at the University of Alabama at Birmingham.","award":["No number"],"award-info":[{"award-number":["No number"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12916-017-0816-6","type":"journal-article","created":{"date-parts":[[2017,3,11]],"date-time":"2017-03-11T03:41:25Z","timestamp":1489203685000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data"],"prefix":"10.1186","volume":"15","author":[{"given":"Jasvinder A.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"issue":"8","key":"816_CR1","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/art.22014","volume":"54","author":"E Krishnan","year":"2006","unstructured":"Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688\u201396.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"816_CR2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/rheumatology\/kes169","volume":"52","author":"CF Kuo","year":"2013","unstructured":"Kuo CF, Yu KH, See LC, Chou IJ, Ko YS, Chang HC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford). 2013;52(1):111\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"816_CR3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/rheumatology\/ket293","volume":"52","author":"OO Seminog","year":"2013","unstructured":"Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford). 2013;52(12):2251\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"816_CR4","doi-asserted-by":"crossref","first-page":"R10","DOI":"10.1186\/ar3684","volume":"14","author":"E Krishnan","year":"2012","unstructured":"Krishnan E, Pandya BJ, Lingala B, Hariri A, Dabbous O. Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther. 2012;14(1):R10.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"816_CR5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","volume":"168","author":"E Krishnan","year":"2008","unstructured":"Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104\u201310.","journal-title":"Arch Intern Med"},{"issue":"8","key":"816_CR6","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894\u2013900.","journal-title":"Circulation"},{"issue":"2","key":"816_CR7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/acr.20065","volume":"62","author":"SY Kim","year":"2010","unstructured":"Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170\u201380.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"816_CR8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/art.24612","volume":"61","author":"SY Kim","year":"2009","unstructured":"Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(7):885\u201392.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"816_CR9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/annrheumdis-2015-208161","volume":"75","author":"SC Kim","year":"2016","unstructured":"Kim SC, Liu J, Solomon DH. Risk of incident atrial fibrillation in gout: a cohort study. Ann Rheum Dis. 2016;75(8):1473\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"816_CR10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/rheumatology\/kev418","volume":"55","author":"CF Kuo","year":"2016","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Impact of gout on the risk of atrial fibrillation. Rheumatology (Oxford). 2016;55(4):721\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"816_CR11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijcard.2014.11.024","volume":"177","author":"F Sanchis-Gomar","year":"2014","unstructured":"Sanchis-Gomar F, Perez-Quilis C, Cervellin G, Lucia A, Lippi G. Anti-gout drugs as potential therapy for atrial fibrillation. Int J Cardiol. 2014;177(3):1061\u20132.","journal-title":"Int J Cardiol"},{"issue":"10","key":"816_CR12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.recesp.2012.03.027","volume":"65","author":"B Benito","year":"2012","unstructured":"Benito B, Josephson ME. Ventricular tachycardia in coronary artery disease. Rev Esp Cardiol (Engl Ed). 2012;65(10):939\u201355.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"816_CR13","doi-asserted-by":"crossref","first-page":"M178","DOI":"10.1093\/gerona\/57.3.M178","volume":"57","author":"WS Aronow","year":"2002","unstructured":"Aronow WS, Ahn C, Mercando AD, Epstein S, Kronzon I. Prevalence and association of ventricular tachycardia and complex ventricular arrhythmias with new coronary events in older men and women with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2002;57(3):M178\u2013180.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"41","key":"816_CR14","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"SG Priori","year":"2015","unstructured":"Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793\u2013867.","journal-title":"Eur Heart J"},{"issue":"10","key":"816_CR15","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1161\/CIRCULATIONAHA.106.178233","volume":"114","author":"DP Zipes","year":"2006","unstructured":"Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC\/AHA\/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology\/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385\u2013484.","journal-title":"Circulation"},{"issue":"1","key":"816_CR16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/annrheumdis-2015-209008","volume":"76","author":"JA Singh","year":"2017","unstructured":"Singh JA, Yu S. Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data. Ann Rheum Dis. 2017;76(1):72\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"816_CR17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1161\/01.RES.55.4.545","volume":"55","author":"AS Manning","year":"1984","unstructured":"Manning AS, Coltart DJ, Hearse DJ. Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol. Circ Res. 1984;55(4):545\u20138.","journal-title":"Circ Res"},{"issue":"2 Pt 2","key":"816_CR18","first-page":"H341","volume":"263","author":"GR Li","year":"1992","unstructured":"Li GR, Ferrier GR. Effects of allopurinol on reperfusion arrhythmias in isolated ventricles. Am J Physiol. 1992;263(2 Pt 2):H341\u2013348.","journal-title":"Am J Physiol"},{"issue":"3","key":"816_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00054636","volume":"2","author":"R Crome","year":"1988","unstructured":"Crome R, Manning AS. Allopurinol and reperfusion-induced arrhythmias: increased protection by simultaneous administration of anti-oxidant enzymes. Cardiovasc Drugs Ther. 1988;2(3):295\u2013304.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"816_CR20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/01.RES.0000148635.73331.c5","volume":"95","author":"LB Stull","year":"2004","unstructured":"Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004;95(10):1005\u201311.","journal-title":"Circ Res"},{"issue":"10","key":"816_CR21","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/j.1540-8167.2012.02356.x","volume":"23","author":"M Sakabe","year":"2012","unstructured":"Sakabe M, Fujiki A, Sakamoto T, Nakatani Y, Mizumaki K, Inoue H. Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Electrophysiol. 2012;23(10):1130\u20135.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"3","key":"816_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10157-014-1012-z","volume":"19","author":"D Bayram","year":"2015","unstructured":"Bayram D, Tugrul Sezer M, Inal S, Altuntas A, Kidir V, Orhan H. The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. Clin Exp Nephrol. 2015;19(3):443\u20139.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"816_CR23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/01.HYP.35.3.746","volume":"35","author":"R Butler","year":"2000","unstructured":"Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35(3):746\u201351.","journal-title":"Hypertension"},{"issue":"22","key":"816_CR24","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","volume":"105","author":"W Doehner","year":"2002","unstructured":"Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105(22):2619\u201324.","journal-title":"Circulation"},{"issue":"3","key":"816_CR25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/08037051.2010.538977","volume":"20","author":"A Dogan","year":"2011","unstructured":"Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011;20(3):182\u20137.","journal-title":"Blood Press"},{"issue":"9732","key":"816_CR26","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"A Noman","year":"2010","unstructured":"Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161\u20137.","journal-title":"Lancet"},{"issue":"5","key":"816_CR27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/HYPERTENSIONAHA.114.03953","volume":"64","author":"CJ Beattie","year":"2014","unstructured":"Beattie CJ, Fulton RL, Higgins P, Padmanabhan S, McCallum L, Walters MR, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension. 2014;64(5):1102\u20137.","journal-title":"Hypertension"},{"issue":"8","key":"816_CR28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","volume":"300","author":"DI Feig","year":"2008","unstructured":"Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924\u201332.","journal-title":"JAMA"},{"issue":"24","key":"816_CR29","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.jacc.2013.07.074","volume":"62","author":"BR Szwejkowski","year":"2013","unstructured":"Szwejkowski BR, Gandy SJ, Rekhraj S, Houston JG, Lang CC, Morris AD, et al. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013;62(24):2284\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"816_CR30","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2012.09.066","volume":"61","author":"S Rekhraj","year":"2013","unstructured":"Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61(9):926\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"816_CR31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2009","volume":"91","author":"U Schotten","year":"2011","unstructured":"Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91(1):265\u2013325.","journal-title":"Physiol Rev"},{"issue":"5","key":"816_CR32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jama.2012.9014","volume":"308","author":"VL Tseng","year":"2012","unstructured":"Tseng VL, Yu F, Lum F, Coleman AL. Risk of fractures following cataract surgery in Medicare beneficiaries. JAMA. 2012;308(5):493\u2013501.","journal-title":"JAMA"},{"issue":"9","key":"816_CR33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2010.216","volume":"303","author":"H Wunsch","year":"2010","unstructured":"Wunsch H, Guerra C, Barnato AE, Angus DC, Li G, Linde-Zwirble WT. Three-year outcomes for Medicare beneficiaries who survive intensive care. JAMA. 2010;303(9):849\u201356.","journal-title":"JAMA"},{"issue":"6","key":"816_CR34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"816_CR35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2125.2008.03249.x","volume":"66","author":"S Hennessy","year":"2008","unstructured":"Hennessy S, Leonard CE, Newcomb C, Kimmel SE, Bilker WB. Cisapride and ventricular arrhythmia. Br J Clin Pharmacol. 2008;66(3):375\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"816_CR36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pds.2340","volume":"21","author":"L Tamariz","year":"2012","unstructured":"Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying ventricular arrhythmias using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:148\u201353.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"816_CR37","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","volume":"84","author":"DY Lin","year":"1989","unstructured":"Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074\u20138.","journal-title":"J Am Stat Assoc"},{"key":"816_CR38","doi-asserted-by":"crossref","first-page":"9656078","DOI":"10.1155\/2016\/9656078","volume":"2016","author":"AA Sovari","year":"2016","unstructured":"Sovari AA. Cellular and molecular mechanisms of arrhythmia by oxidative stress. Cardiol Res Pract. 2016;2016:9656078.","journal-title":"Cardiol Res Pract"},{"issue":"3","key":"816_CR39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/hh1501.094115","volume":"89","author":"D Cesselli","year":"2001","unstructured":"Cesselli D, Jakoniuk I, Barlucchi L, Beltrami AP, Hintze TH, Nadal-Ginard B, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ Res. 2001;89(3):279\u201386.","journal-title":"Circ Res"},{"issue":"5","key":"816_CR40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semnephrol.2011.08.007","volume":"31","author":"W Doehner","year":"2011","unstructured":"Doehner W, Landmesser U. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol. 2011;31(5):433\u201340.","journal-title":"Semin Nephrol"},{"issue":"4","key":"816_CR41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1755-5922.2011.00277.x","volume":"30","author":"P Higgins","year":"2012","unstructured":"Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012;30(4):217\u201326.","journal-title":"Cardiovasc Ther"},{"key":"816_CR42","doi-asserted-by":"crossref","first-page":"282059","DOI":"10.1155\/2009\/282059","volume":"2009","author":"P Higgins","year":"2009","unstructured":"Higgins P, Dawson J, Walters M. The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc Psychiatry Neurol. 2009;2009:282059.","journal-title":"Cardiovasc Psychiatry Neurol"},{"issue":"1","key":"816_CR43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87\u2013114.","journal-title":"Pharmacol Rev"},{"issue":"10","key":"816_CR44","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136\u201341.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"816_CR45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13075-016-1111-1","volume":"18","author":"JA Singh","year":"2016","unstructured":"Singh JA, Yu S. Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims. Arthritis Res Ther. 2016;18(1):209.","journal-title":"Arthritis Res Ther"},{"key":"816_CR46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12883-016-0692-2","volume":"16","author":"JA Singh","year":"2016","unstructured":"Singh JA, Yu S. Allopurinol and the risk of stroke in older adults receiving Medicare. BMC Neurol. 2016;16:164.","journal-title":"BMC Neurol"},{"issue":"2","key":"816_CR47","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.coph.2013.01.001","volume":"13","author":"TM Kolettis","year":"2013","unstructured":"Kolettis TM. Coronary artery disease and ventricular tachyarrhythmia: pathophysiology and treatment. Curr Opin Pharmacol. 2013;13(2):210\u20137.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"816_CR48","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.hrthm.2016.01.019","volume":"13","author":"B Mondesert","year":"2016","unstructured":"Mondesert B, Khairy P, Schram G, Shohoudi A, Talajic M, Andrade JG, et al. Impact of revascularization in patients with sustained ventricular arrhythmias, prior myocardial infarction, and preserved left ventricular ejection fraction. Heart Rhythm. 2016;13(6):1221\u20137.","journal-title":"Heart Rhythm"},{"issue":"3","key":"816_CR49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4065\/84.3.289","volume":"84","author":"BA Koplan","year":"2009","unstructured":"Koplan BA, Stevenson WG. Ventricular tachycardia and sudden cardiac death. Mayo Clin Proc. 2009;84(3):289\u201397.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"816_CR50","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.hrthm.2011.06.036","volume":"8","author":"JM Diego Di","year":"2011","unstructured":"Di Diego JM, Antzelevitch C. Ischemic ventricular arrhythmias: experimental models and their clinical relevance. Heart Rhythm. 2011;8(12):1963\u20138.","journal-title":"Heart Rhythm"},{"issue":"4","key":"816_CR51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.hrthm.2011.11.008","volume":"9","author":"PM Okin","year":"2012","unstructured":"Okin PM, Kjeldsen SE, Julius S, Dahlof B, Devereux RB. Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE study. Heart Rhythm. 2012;9(4):531\u20137.","journal-title":"Heart Rhythm"},{"issue":"9","key":"816_CR52","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJM199308263290902","volume":"329","author":"LB Becker","year":"1993","unstructured":"Becker LB, Han BH, Meyer PM, Wright FA, Rhodes KV, Smith DW, et al. Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR Chicago Project. N Engl J Med. 1993;329(9):600\u20136.","journal-title":"N Engl J Med"},{"issue":"12","key":"816_CR53","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jacc.2011.01.049","volume":"58","author":"RE Eckart","year":"2011","unstructured":"Eckart RE, Shry EA, Burke AP, McNear JA, Appel DA, Castillo-Rojas LM, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol. 2011;58(12):1254\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"816_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","volume":"22","author":"ES Johnson","year":"2013","unstructured":"Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-017-0816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T22:56:27Z","timestamp":1719096987000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-017-0816-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1186\/s12916-017-0816-6","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,22]]},"article-number":"59"}}